INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025

Core Insights - International Isotopes Inc. reported a revenue of $3,277,816 for Q3 2025, a decrease of 16% compared to the same period last year, while revenue for the nine months ended September 30, 2025, was $10,172,036, an increase of 2% year-over-year [1][8] - The company experienced a net loss of $203,601 in Q3 2025, a significant decline from a net profit of $150,251 in Q3 2024, with a total net loss of $477,080 for the first nine months of 2025, an increase in loss of 101% from the previous year [1][9] - The decrease in revenue was primarily attributed to outages of raw materials for Theranostics Products and Calibration & Reference Products, which the company estimates reduced revenues by over $400,000 in Q3 and over $750,000 for the nine months [1][2] Financial Performance - Revenue from Theranostics Products for the first nine months of 2025 was $5,176,740, a decrease of 17% from $6,257,410 in the same period last year, mainly due to outages of I-131 raw material [3][5] - Revenue from Calibration & Reference Products increased by 57% to $3,301,673 for the first nine months of 2025, compared to $2,099,713 in the prior year, driven by the resolution of a global shortage of Cobalt-57 isotope [5][6] - Revenue from Cobalt Products decreased by 8% to $1,517,147 for the first nine months of 2025, compared to $1,641,012 in the same period last year, attributed to the timing of sales [6] Operational Developments - The company has made significant internal improvements, reducing SG&A costs by 24% for the quarter and 11% for the year [3] - The Calibration & Reference Products segment has seen growth and improvements in legacy products, alongside the development of new products [3][5] - The Medical Devices segment generated $176,476 in revenue for the first nine months of 2025, marking its first sales since being established as a reportable segment [7] Segment Analysis - The company received FDA approval for an additional raw material supplier for Theranostics Products, which began supplying in September 2025 [2][3] - The Fluorine Products segment had no sales during the reported periods, with ongoing expenses related to a proposed de-conversion facility [7] - The company anticipates that full-year 2025 revenues in the Calibration & Reference Products segment will reflect historically normal amounts as supply chains normalize [5]